Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sevoflurane + remifentanil is a combination of two pharmaceutical agents commonly used together for the induction and maintenance of general anesthesia. Sevoflurane is a volatile halogenated ether administered by inhalation, acting primarily as a hypnotic agent, while remifentanil is an ultra-short-acting synthetic opioid analgesic administered intravenously. The combination provides both hypnosis (loss of consciousness) and potent analgesia (pain relief), allowing for rapid titration and control during surgical procedures. Their interaction is synergistic, meaning that when used together, lower doses of each drug are required to achieve the desired anesthetic effect compared to when either drug is used alone[1][2][5]. This synergy reduces the risk of side effects such as circulatory depression associated with higher doses of individual agents[1]. The primary indications are for use in inpatient and outpatient surgeries requiring general anesthesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sevoflurane + remifentanil.